You just read:

BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®

News provided by

BerGenBio ASA

Apr 10, 2018, 02:20 ET